SCL14 Antibody

What is SCL14 and why are antibodies against it important in plant research?

SCL14 is a member of the GRAS family of regulatory proteins that functions as a transcriptional co-activator by interacting with class II TGA transcription factors (TGA2, TGA5, and TGA6). This interaction plays a crucial role in activating TGA-dependent but NPR1-independent stress responses . SCL14 antibodies enable researchers to study protein-protein interactions, chromatin occupancy patterns, and subcellular localization dynamics. These antibodies are essential for chromatin immunoprecipitation (ChIP) experiments that reveal how SCL14 is recruited to promoters of genes involved in xenobiotic detoxification pathways . Furthermore, SCL14 appears to function as a repressor in lignin biosynthesis by inhibiting the NAC043-MYB61 signaling cascade, making these antibodies valuable for studying both stress responses and developmental processes .

What types of experimental applications can SCL14 antibodies be used for?

SCL14 antibodies can be deployed in diverse experimental contexts. In Western blotting, they allow detection of SCL14 protein expression levels across different tissues or treatment conditions . For protein interaction studies, these antibodies enable co-immunoprecipitation (Co-IP) experiments to identify SCL14 binding partners, such as TGA transcription factors . ChIP assays using SCL14 antibodies have successfully demonstrated recruitment of SCL14 to target promoters containing as-1-like elements, including those of genes like CYP81D11, MtN19-like, and GSTU7 . Immunofluorescence microscopy with these antibodies has revealed that SCL14 is localized in both the nucleus and cytosol, with nuclear export being sensitive to Leptomycin B treatment . Additionally, SCL14 antibodies have proven valuable in chromatin immunoprecipitation experiments comparing wild-type plants with scl14 and tga2 tga5 tga6 mutants to demonstrate dependence on TGA factors for SCL14 recruitment to target promoters .

How should SCL14 antibodies be validated before use in experiments?

Thorough validation of SCL14 antibodies is essential for ensuring experimental reliability. The most critical validation step is testing specificity using wild-type plant tissue alongside scl14 mutant tissue as a negative control. Previous studies have successfully used the Arabidopsis SALK_126931 T-DNA insertion line, which shows no detectable SCL14 protein, as a negative control for antibody validation . Western blot analysis should show absence of the appropriate band in the scl14 mutant while detecting a protein of approximately 70-75 kDa in wild-type samples . For antibodies intended for ChIP applications, preliminary testing should confirm enrichment of known SCL14 target promoters (such as CYP81D11) compared to non-target genomic regions . Additionally, competition assays with recombinant SCL14 protein or the immunogenic peptide can verify specificity by showing signal reduction when the antibody is pre-incubated with its antigen. Cross-reactivity tests against related GRAS family proteins help establish the antibody's selectivity within this protein family.

What controls should be included when using SCL14 antibodies in experimental procedures?

Appropriate controls are critical for experiments employing SCL14 antibodies. For Western blotting, protein extracts from scl14 knockout plants serve as essential negative controls to verify antibody specificity . When performing immunoprecipitation or ChIP experiments, include an isotype control (non-specific IgG from the same species) to assess background binding . In ChIP experiments targeting SCL14-regulated promoters, include amplification of non-target genomic regions lacking as-1-like elements as negative controls . For gene expression studies correlating with SCL14 function, include the NPR1-dependent PR-1 gene as a negative control that is not regulated by SCL14 . When studying protein-protein interactions, validate the specificity of detected interactions by performing reciprocal co-IPs and including appropriate controls for non-specific binding to the matrix . For immunofluorescence microscopy, include controls for autofluorescence and secondary antibody-only binding to distinguish specific from non-specific signals .

What is the optimal protocol for using SCL14 antibodies in chromatin immunoprecipitation (ChIP) experiments?

Successful ChIP experiments with SCL14 antibodies require careful optimization of each protocol step. For crosslinking, fresh plant material (preferably 3-4 week old seedlings) should be treated with 1% formaldehyde for 10 minutes under vacuum followed by quenching with 0.125 M glycine . Nuclear isolation should be performed using an extraction buffer containing 0.4 M sucrose, 10 mM Tris-HCl (pH 8.0), 10 mM MgCl₂, 5 mM β-mercaptoethanol, and protease inhibitors . For chromatin shearing, sonication should be optimized to generate fragments between 200-500 bp. Immunoprecipitation should include pre-clearing with protein A/G beads before incubation with the SCL14 antibody overnight at 4°C . When designing PCR primers for ChIP-qPCR analysis, target regions containing as-1-like elements in promoters of known SCL14-regulated genes such as CYP81D11, MtN19-like, and GSTU7 . Essential controls include input chromatin (non-immunoprecipitated), IgG control antibody, and chromatin from scl14 mutant plants . For data normalization, expressing results as percent input after adjustment with a reference gene (like ACTIN8) provides the most reliable quantification .

How can I optimize Western blot conditions for detecting SCL14 protein in plant extracts?

Detecting SCL14 by Western blotting requires optimization of several parameters. For protein extraction, use a buffer containing detergents suitable for nuclear proteins (such as 1% Triton X-100 with 0.1% SDS) and include protease inhibitors to prevent degradation . Since SCL14 is approximately 70-75 kDa, use 8-10% SDS-PAGE gels for optimal resolution . Transfer to PVDF membrane at 100V for 1.5 hours or 30V overnight at 4°C to ensure complete transfer of larger proteins. For blocking, 5% non-fat dry milk in TBST (1 hour at room temperature) effectively reduces background binding . Primary SCL14 antibody dilutions typically range from 1:1000 to 1:5000 depending on antibody quality, with overnight incubation at 4°C yielding the best results . After washing thoroughly with TBST (4-5 times, 5-10 minutes each), apply HRP-conjugated secondary antibody (1:5000 to 1:10000) for 1 hour at room temperature . When troubleshooting weak signals, consider concentrating the protein sample, reducing antibody dilution, or using enhanced chemiluminescence substrates. For high background, increase washing time, use higher antibody dilutions, or pre-adsorb the primary antibody with non-specific proteins.

What considerations are important when using SCL14 antibodies for immunofluorescence microscopy?

Immunofluorescence microscopy with SCL14 antibodies requires attention to several key factors. For sample preparation, fresh tissue fixation in 4% paraformaldehyde is critical for preserving protein localization while maintaining epitope accessibility . Given SCL14's nuclear-cytoplasmic distribution, permeabilization with 0.1-0.3% Triton X-100 is essential for antibody penetration into both compartments . Blocking with 5% BSA for at least 1 hour minimizes non-specific binding. Primary SCL14 antibody dilutions typically range from 1:100 to 1:500 for tissue sections, with overnight incubation at 4°C . Secondary antibodies should be selected to minimize cross-reactivity with plant proteins, and fluorophores in the red to far-red spectrum often reduce interference from plant autofluorescence. When interpreting SCL14 localization patterns, remember that the protein shows dual localization in both nucleus and cytoplasm under normal conditions . Treatment with nuclear export inhibitor Leptomycin B (LMB) can be used to confirm the involvement of exportin-mediated nuclear export in SCL14 localization . Essential controls include scl14 mutant tissues, pre-immune serum controls, and secondary antibody-only controls to distinguish specific from non-specific signals .

How can I study the dynamics of SCL14-TGA interactions in response to xenobiotic stress?

Investigating SCL14-TGA interaction dynamics under xenobiotic stress requires complementary approaches. Co-immunoprecipitation experiments should be performed on tissues treated with xenobiotics like 2,4-D or salicylic acid across a time course (0, 1, 3, 6, 12, 24 hours) . For protein extraction, use buffers that preserve protein-protein interactions while still solubilizing nuclear proteins, such as 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and protease inhibitors . After immunoprecipitation with anti-SCL14 antibodies, probe membranes with antibodies against TGA2/5/6 to detect interaction changes over time . ChIP-seq analysis with SCL14 antibodies on tissues before and after xenobiotic treatment can identify stress-induced changes in genomic binding patterns . Sequential ChIP (first with anti-TGA antibodies followed by anti-SCL14) can identify genomic regions where both proteins co-localize specifically during stress responses . For in vivo validation, bimolecular fluorescence complementation (BiFC) using SCL14 and TGA fusion constructs allows visualization of interaction dynamics in living cells under various treatments . Real-time PCR analysis of known SCL14 target genes (CYP81D11, MtN19-like, GSTU7) provides functional readouts of SCL14-TGA complex activity in response to stress treatments .

What approaches can be used to investigate post-translational modifications of SCL14 using specific antibodies?

Post-translational modifications (PTMs) of SCL14 can be investigated using several complementary techniques. For phosphorylation studies, immunoprecipitate SCL14 using validated antibodies and analyze samples with and without phosphatase treatment to observe mobility shifts on SDS-PAGE . Western blotting with phospho-specific antibodies (if available) can directly detect phosphorylated forms of SCL14 under different treatment conditions. For mass spectrometry analysis, perform large-scale immunoprecipitation of SCL14 from plants under different treatment conditions (control, SA, 2,4-D) using specific antibodies . Digest purified protein and analyze by LC-MS/MS to identify modification sites. Two-dimensional gel electrophoresis followed by Western blotting with SCL14 antibodies can reveal different modified forms based on charge and molecular weight differences . To investigate whether PTMs affect SCL14-TGA interactions, perform co-immunoprecipitation experiments after treatments that induce specific modifications (such as kinase or phosphatase inhibitors) and quantify the amount of co-precipitated TGA factors . ChIP experiments with SCL14 antibodies under conditions that alter PTM status can reveal how modifications affect DNA binding capacity or target gene specificity .

How can I use SCL14 antibodies to investigate the competition between SCL14 and NPR1 for TGA factor binding?

Investigating competition between SCL14 and NPR1 for TGA factor binding requires specialized experimental approaches. Sequential co-immunoprecipitation can be employed by first immunoprecipitating with anti-TGA antibodies, then mildly eluting complexes and performing secondary immunoprecipitations with either anti-SCL14 or anti-NPR1 antibodies . Competitive binding assays can be designed by immobilizing recombinant TGA factors on an affinity matrix, then incubating with varying ratios of purified SCL14 and NPR1 proteins before analyzing bound fractions by Western blotting with respective antibodies . Chromatin immunoprecipitation experiments with both anti-SCL14 and anti-NPR1 antibodies targeting the same TGA-regulated promoters can reveal whether occupancy patterns change reciprocally under different treatment conditions (e.g., SA treatment) . When designing these experiments, keep in mind that SCL14 interacts with TGA factors to regulate NPR1-independent genes (such as GSTs), while NPR1 interacts with TGA factors to regulate distinct sets of genes (such as PR-1) . For functional validation, use reporter gene assays with promoters containing as-1-like elements and co-express varying levels of SCL14 and NPR1 to assess functional competition .

What methodologies can help resolve contradictory data when SCL14 antibodies show different patterns of protein localization?

When facing contradictory SCL14 localization data, several methodological approaches can help resolve discrepancies. First, compare antibodies targeting different epitopes of SCL14 to determine if epitope masking or post-translational modifications affect detection in specific cellular compartments . Validate each antibody's specificity using scl14 mutant controls and peptide competition assays . Compare different fixation protocols (paraformaldehyde, methanol, acetone) to assess their effects on epitope accessibility and cellular structure preservation. For definitive localization data, complement antibody-based methods with fluorescent protein-tagged SCL14 constructs, comparing fixed samples with live-cell imaging . Consider that SCL14 shows both nuclear and cytoplasmic localization, with dynamic shuttling affected by nuclear export mechanisms (as demonstrated by Leptomycin B sensitivity) . Perform subcellular fractionation followed by Western blotting to quantitatively assess protein distribution between compartments. Importantly, test different biological conditions, as SCL14 localization may change in response to stress treatments (SA, 2,4-D) or developmental cues . Document treatment conditions precisely when reporting localization data, as the protein's distribution is dynamic rather than static .

How can SCL14 antibodies be used to elucidate the role of SCL14 in the gibberellin signaling pathway?

SCL14 antibodies provide valuable tools for investigating the relationship between SCL14 and gibberellin (GA) signaling. Co-immunoprecipitation experiments using SCL14 antibodies followed by detection of DELLA proteins (especially GAI) can reveal direct interactions between these regulatory proteins . Compare these interactions in GA-treated versus untreated plants to determine how hormone treatment affects complex formation . ChIP analysis with SCL14 antibodies on promoters of lignin biosynthesis genes can assess whether GA treatment alters SCL14 binding patterns . For protein stability analysis, treat plants with GA and cycloheximide, then use SCL14 antibodies to monitor protein levels over time by Western blotting to determine if GA affects SCL14 stability . Immunohistochemistry with SCL14 antibodies in wild-type, GA-deficient, and GA-insensitive mutants can reveal tissue-specific changes in SCL14 abundance and distribution . When interpreting results, consider that SCL14 appears to inhibit the NAC043-MYB61 signaling cascade in lignin biosynthesis, functioning as a key repressor in the GA signaling pathway . Quantitative real-time PCR can be used to correlate SCL14 protein levels (detected by antibodies) with expression of downstream genes involved in lignin biosynthesis, such as PAL, COMT, HCT, and POD .

What strategies can resolve conflicting data about SCL14's role in detoxification versus lignin biosynthesis pathways?

Resolving SCL14's dual roles in detoxification and lignin biosynthesis requires integrative approaches. Comprehensive ChIP-seq analysis with SCL14 antibodies under multiple conditions (xenobiotic stress, developmental stages with active lignification, and various hormone treatments) can identify condition-specific binding sites and regulatory targets . Tissue-specific immunohistochemistry using SCL14 antibodies can compare protein localization in vascular tissues undergoing lignification versus tissues responding to xenobiotic stress . Protein complex analysis through immunoprecipitation followed by mass spectrometry from different tissue contexts can identify tissue-specific interaction partners that may mediate different functions . When interpreting ChIP data, examine the promoter elements of target genes to determine if different DNA motifs mediate binding in different pathways . Gene expression analysis should compare how SCL14 affects both detoxification genes (GSTs, CYPs) and lignin biosynthesis genes (PAL, COMT) across different conditions . Consider that SCL14 appears to have opposite regulatory functions in these pathways - acting as an activator in detoxification responses through TGA interactions but as a repressor in lignin biosynthesis by inhibiting NAC043-MYB61 signaling .

How can I use SCL14 antibodies to investigate the relationship between xenobiotic stress response and development in plants?

Investigating the intersection of stress responses and development using SCL14 antibodies requires a multifaceted approach. Perform developmental time-course analysis by collecting tissues at different growth stages and using Western blots with SCL14 antibodies to track expression levels . Compare SCL14 protein patterns in vegetative versus reproductive structures to identify developmental regulation of this stress response regulator . ChIP-seq analysis with SCL14 antibodies across developmental stages can identify stage-specific binding patterns and regulatory targets . Chromatin co-immunoprecipitation comparing binding patterns of SCL14 and developmental transcription factors can identify shared regulatory regions between stress and developmental pathways . For tissue-specific analysis, use immunohistochemistry with SCL14 antibodies to map protein distribution across different tissues and developmental zones . Investigate hormone cross-talk by examining SCL14 protein levels in hormone biosynthesis/signaling mutants (especially GA signaling components) . Consider that SCL14's role in lignin biosynthesis links stress responses with developmental processes, as lignification is both a developmental program and a stress response . Correlate SCL14 binding patterns (via ChIP) with expression of target genes during development to identify stage-specific regulatory mechanisms .

What are common pitfalls when using SCL14 antibodies and how can they be addressed?

Several common challenges arise when working with SCL14 antibodies. In Western blots, high background or multiple bands may occur due to non-specific binding or protein degradation . To address this, increase blocking time (2-3 hours), optimize antibody dilution (starting from 1:2000), add additional protease inhibitors during extraction, and include phosphatase inhibitors if studying phosphorylation . For weak or inconsistent immunoprecipitation results, increase starting material, try different extraction buffers with mild detergents, and extend incubation times . In ChIP experiments, inconsistent results may stem from inefficient crosslinking or variable sonication . Optimize crosslinking time (typically 10 minutes for formaldehyde), standardize sonication conditions to achieve consistent fragment sizes (200-500 bp), and include multiple positive and negative control regions . For immunofluorescence, high background or non-specific staining can be addressed by extending blocking time, reducing primary antibody concentration, and implementing more stringent washing procedures . When interpreting SCL14 localization data, remember that the protein is found in both nucleus and cytoplasm and shuttles between compartments in an exportin-dependent manner, as demonstrated by Leptomycin B treatment effects . Always validate antibody specificity using scl14 mutant controls before concluding experimental problems are technical rather than biological .

How can SCL14 antibodies be used to investigate protein-protein interaction networks in stress signaling pathways?

SCL14 antibodies enable comprehensive analysis of protein interaction networks in stress signaling. Co-immunoprecipitation followed by mass spectrometry can identify all proteins interacting with SCL14 under different stress conditions . Initially demonstrated interactions with TGA factors can be expanded to discover novel partners involved in different aspects of stress signaling . For validating specific interactions, perform reciprocal co-IPs with antibodies against suspected partners (TGA factors, DELLA proteins) and confirm presence of SCL14 . Sequential co-immunoprecipitation can build interaction hierarchies by first precipitating with SCL14 antibodies, then using the eluate for second-round IPs with antibodies against other proteins . For chromatin-associated complexes, perform ChIP-reChIP (sequential ChIP) to identify genomic regions where SCL14 co-localizes with interaction partners . Compare interaction networks between xenobiotic stress conditions and developmental contexts to identify condition-specific interactions . Remember that SCL14 interacts with TGA factors in detoxification pathways but appears to interact with components of the GA signaling pathway in the context of lignin biosynthesis regulation . For functional validation of interactions, correlate protein complex formation with expression of downstream target genes in appropriate genetic backgrounds (wild-type, scl14, tga2/5/6) .

What strategies can be employed when working with low abundance or difficult-to-detect SCL14 protein?

Detecting low-abundance SCL14 protein requires optimization of several experimental parameters. For protein extraction, increase starting material (50-100 mg tissue per sample) and use specialized buffers containing stronger detergents (0.1-0.5% SDS with 1% Triton X-100) to improve nuclear protein solubilization . Consider protein concentration methods such as TCA precipitation or vacuum concentration before loading gels. For Western blotting, use high-sensitivity detection systems like enhanced chemiluminescence substrates or fluorescence-based detection . Implement signal amplification systems such as biotin-streptavidin detection or tyramide signal amplification for immunohistochemistry applications . For immunoprecipitation of low-abundance SCL14, use larger amounts of starting material, extend incubation times (overnight at 4°C), and consider crosslinking approaches to stabilize transient interactions . In ChIP experiments with limited material, adapt micro-ChIP protocols using smaller amounts of starting material with optimized sonication and IP conditions . Consider using transgenic plants expressing epitope-tagged SCL14 under its native promoter if antibody sensitivity is consistently limiting . For tissue-specific studies, enrich for tissues known to express higher levels of SCL14 based on previous expression data, particularly tissues responding to xenobiotic stress or undergoing active lignification .

How can SCL14 antibodies be applied to study lignin biosynthesis regulation in tree species?

SCL14 antibodies provide valuable tools for studying lignin biosynthesis in woody species like Populus. In recent studies with Populus hopeiensis, SCL14 has been identified as a key repressor in lignin biosynthesis regulation, functioning through inhibition of the NAC043-MYB61 signaling cascade . When applying SCL14 antibodies in tree species research, consider that protein extraction from lignified tissues requires more stringent conditions - use buffers containing higher detergent concentrations (1-2% Triton X-100 with 0.2-0.5% SDS) and longer extraction times . For developmental studies, compare SCL14 protein levels across different ages of plant material (3, 6, and 9 months) using Western blotting to correlate with lignification patterns . ChIP experiments with SCL14 antibodies can target promoters of lignin biosynthesis genes such as PAL, COMT, HCT, and POD to assess direct regulatory interactions . Co-immunoprecipitation can investigate interactions between SCL14 and lignin-specific transcription factors like NAC043 and MYB61 . When interpreting results, consider that SCL14 expression appears inversely correlated with NAC043 expression, suggesting mutual inhibition mechanisms . Interestingly, SCL14 expression is significantly upregulated in tetraploid poplars, which show reduced lignin content compared to diploids, providing a system to study SCL14's role in ploidy-dependent lignin regulation .

What considerations are important when using SCL14 antibodies for comparative studies across plant species?

Cross-species applications of SCL14 antibodies require careful consideration of several factors. Epitope conservation is paramount - align SCL14 protein sequences across target species to identify conserved regions likely to be recognized by the antibody . Post-translational modification patterns may differ between species even when primary sequences are conserved, potentially affecting epitope recognition . When testing SCL14 antibodies in new species, perform basic validation through Western blotting alongside a positive control (typically Arabidopsis extract) . Antibody dilutions likely need optimization for each species - typically more concentrated antibody solutions are required when moving beyond the species against which the antibody was raised . For immunoprecipitation applications, buffer conditions may need species-specific adjustment to account for differences in interfering compounds . In ChIP experiments across species, confirm that regulatory elements in target gene promoters are sufficiently conserved to warrant comparison . Consider evolutionary distance when interpreting cross-species results - SCL14 function appears conserved between Arabidopsis and Populus (both dicots), but may differ substantially in monocots . Document and standardize protocols for each species tested, noting optimal conditions and limitations specific to each plant system .